Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company that discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company focuses on novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Its lead compound, XPOVIO, is used in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL, as well as ELTANEXOR for treating Myelodysplastic Neoplasms, and other compounds such as verdinexor, KPT-9274, and IL-12.
In addition, Karyopharm has a license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications. It also has a license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications.
Furthermore, the company has a distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Karyopharm also collaborates with Bristol Myers Squibb to evaluate the novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
